Alnylam stock jumps after Q2 earnings beat and higher 2025 guidance, led by Amvuttra's rapid uptake and strong growth across ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

The better-than-expected launch of a rare heart disease drug pushed Alnylam (Nasdaq: ALNY) past the $50 billion market ...

We can see that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) does use debt in its business. But is this debt a concern to shareholders? Debt assists a business until the business has trouble paying it ...

Q2 2025 Earnings Call Transcript July 31, 2025 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ・ALNY has a 100% technical ...

Alnylam Pharmaceuticals's Current Market Status With a volume of 446,657, the price of ALNY is up 0.74% at $233.99. RSI indicators hint that the underlying stock may be oversold.

10 analysts have expressed a variety of opinions on Alnylam Pharmaceuticals (NASDAQ:ALNY) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you ...

Morgan Stanley cut their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating for the company in a report on Friday, April 11th.

Scotiabank lifted their target price on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a “sector outperform” rating in a research report on Friday, March 21st.